Dihydropyridine derivatives modulate heat shock responses and have a neuroprotective effect in a transgenic mouse model of Alzheimer’s disease by Kasza, Ágnes et al.
Dihydropyridine derivatives modulate heat shock responses 
and have a neuroprotective effect in a transgenic mouse 
model of Alzheimer’s disease
Article  (Published Version)
http://sro.sussex.ac.uk
Kasza, Ágnes, Hunya, Ákos, Frank, Zsuzsa, Fülöp, Ferenc, Török, Zsolt, Balogh, Gábor, Sántha, 
Miklós, Bálind, Árpád, Bernáth, Sándor, Blundell, Katie L I M, Prodromou, Chrisostomos, Horváth, 
Ibolya, Zeiler, Hans-Joachim, Hooper, Philip L, Vigh, László et al. (2016) Dihydropyridine 
derivatives modulate heat shock responses and have a neuroprotective effect in a transgenic 
mouse model of Alzheimer’s disease. Journal of Alzheimer's Disease, 53 (2). pp. 557-571. ISSN 
1387-2877 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/60402/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
Journal of Alzheimer’s Disease 53 (2016) 557–571
DOI 10.3233/JAD-150860
IOS Press
557
Dihydropyridine Derivatives Modulate
Heat Shock Responses and have
a Neuroprotective Effect in a Transgenic
Mouse Model of Alzheimer’s Disease
´Agnes Kaszaa,1, ´Akos Hunyab,1, Zsuzsa Franka, Ferenc Fu¨lo¨pc, Zsolt To¨ro¨kb,d, Ga´bor Baloghd,
Miklo´s Sa´nthad, ´Arpa´d Ba´lindd, Sa´ndor Berna´the, Katie L.I.M. Blundellf , Chrisostomos Prodromouf ,
Ibolya Horva´thd, Hans-Joachim Zeilerg, Philip L. Hooperh, La´szlo´ Vighd,∗ and Botond Penkea,∗
aDepartment of Medical Chemistry, University of Szeged, Szeged, Hungary
bLipidArt Research and Development Ltd., Szeged, Hungary
cDepartment of Pharmaceutical Chemistry, University of Szeged, Szeged, Hungary
dBiological Research Center of HAS, Institute of Biochemistry, Szeged, Hungary
eFontaMed Consulting Ltd., Telki, Hungary
fGenome Damage and Stability Centre, University of Sussex, Falmer, Brighton, UK
gCreative Therapeutics GmbH, Wuppertal, Nordrhein-Westfalen, Germany
hDivision of Endocrinology,Metabolism andDiabetes, Department ofMedicine, University of ColoradoMedical
School, Anschutz Medical Campus, Aurora, CO, USA
Handling Associate Editor: Jose Abisambra
Accepted 8 April 2016
Abstract. Heat shock proteins (Hsps) have chaperone activity and play a pivotal role in the homeostasis of proteins by
preventing misfolding, by clearing aggregated and damaged proteins from cells, and by maintaining proteins in an active
state. Alzheimer’s disease (AD) is thought to be caused by amyloid- peptide that triggers tau hyperphosphorylation, which is
neurotoxic. Although proteostasis capacity declines with age and facilitates the manifestation of neurodegenerative diseases
such as AD, the upregulation of chaperones improves prognosis. Our research goal is to identify potent Hsp co-inducers
that enhance protein homeostasis for the treatment of AD, especially 1,4-dihydropyridine derivatives optimized for their
ability to modulate cellular stress responses. Based on favorable toxicological data and Hsp co-inducing activity, LA1011
was selected for the in vivo analysis of its neuroprotective effect in the APPxPS1 mouse model of AD. Here, we report
that 6 months of LA1011 administration effectively improved the spatial learning and memory functions in wild type mice
and eliminated neurodegeneration in double mutant mice. Furthermore, Hsp co-inducer therapy preserves the number of
neurons, increases dendritic spine density, and reduces tau pathology and amyloid plaque formation in transgenic AD mice.
In conclusion, the Hsp co-inducer LA1011 is neuroprotective and therefore is a potential pharmaceutical candidate for the
therapy of neurodegenerative diseases, particularly AD.
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INTRODUCTION
Protein quality control requires constant surveil-
lance to prevent proteins misfolding, aggregating
and their subsequent loss of function. Maintenance
of proteome integrity and protein homeostasis (pro-
teostasis) critically depends on a complex network of
heat shock proteins (Hsps) that act as molecular chap-
erones [1]. Small Hsps, together with other members
of the chaperone network such as the Hsp70 pro-
tein family, help maintain normal protein homeostasis
that is essential for cellular function [2]. However,
Hsps decline with age [3, 4] and this correlates with
a loss in the capacity of cells to maintain protein
homeostasis. It is therefore not surprising that the
prevalence of neurodegenerative diseases (NDDs)
such as Alzheimer’s disease (AD) and Parkinson’s
disease increases with age [2, 5]. Hsps play a role in
extending longevity in animal models, but it is unclear
whether this is true in humans [6].
Despite great diversity in the primary amino-
acid sequence of proteins, the oligomers of different
misfolded amyloidogenic proteins (hyperphospho-
rylated tau, amyloid-, -synuclein) elicit toxicity
by common mechanisms [7]. This toxicity involves
membrane perturbations, calcium dysregulation, the
accumulation of reactive oxygen species, endo-
plasmic reticulum (ER)-stress, impairment of the
ubiquitin-proteasome system, and the activation of
apoptotic signaling pathways [8–11]. Indeed, it is
hypothesized that the initiation of NDDs is a result of
ER-stress, damaged mitochondria, and loss of Ca2+-
and protein homeostasis [12–16]. Additionally, ER-
stress caused by ER Ca2+-depletion, hypoxia, and/or
hypoglycemia, initiates the unfolded protein response
(UPR) [17] and prolongs UPR activation thus trigger-
ing apoptotic pathways that result in cell death [18].
Furthermore, mitochondrial energy production fail-
ure and the mitochondria-associated ER membrane
may play key roles in the generation of amyloid pro-
teins and the initiation of NDDs [19, 20].
Maintenance of protein homeostasis by the mod-
ulation of protein processing and folding systems
by chaperone induction are key therapeutic tar-
gets of drug discovery for AD treatment [21]. The
induction of Hsps also offers a potential strategy
for the treatment of other neurodegenerative disor-
ders [22, 23]. Small Hsps (such as Hsp27) bind
to improperly folded, partially denatured proteins,
preventing their aggregation and promoting cell
survival. Recovery is further enhanced when sHsp-
bound proteins are transferred to ATP-dependent
chaperones like Hsp70, which facilitates refolding
[24] or transfer to protein degradation machinery. It
was reported that Hsp27, Hsp70, proteasomes, and
autophagosomes form a complex network that main-
tains protein homeostasis [25, 26]. Hsp27 and Hsp70
are usually co-expressed in response to stress stim-
uli [27]. Sequestration of misfolded proteins into
chaperone-enriched aggregates is a protective strat-
egy that slows the decline of proteostasis during
aging of the nematode Caenorhabditis elegans [28].
Because Hsp27 and 70 have a central role in pro-
tein homeostasis, their induction may prevent and
disassemble toxic protein aggregates, which might
represent a novel target for the treatment of NDDs
[2, 29–37].
Regulation of intracellular Ca2+ levels contributes
to neuronal defense against protein misfolding. Thus,
Ca2+ channel blockers (CCBs) may be putative drugs
for the prevention and treatment of NDDs such as
AD [38–40]. The family of 1,4-dihydropyridines
(DHPs) represents one of the most important groups
of CCBs. DHPs were originally identified as calcium
antagonists (nifedipine) and are widely used to treat
hypertension and heart failure [41]. Substitution of
the CCB molecular nucleus with variety of groups
is the most commonly tested scaffold among L-type
CCBs. These CCB variations result in a plethora of
diverse activities at receptors, channels, transporters,
and metabolizing enzymes [42]. In particular, DHPs
interact with ion channels and G-protein coupled
receptors [43]. CCBs have also been used in demen-
tia therapy and nilvadipine is well tolerated by AD
patients and is a promising candidate for AD treat-
ment [38, 44, 45].
Clinical data suggest that the underlying ther-
apeutic mechanism in AD is independent of the
anti-hypertensive action of the CCB. Longitudinal
studies of elderly people with AD support the use
of CCBs as potential disease progression therapy.
An ongoing advanced clinical trial (CT number
02017340) for the treatment of AD with nilvadipine
is due to close in 2017 [39]. Clinical evidence from
epidemiological studies, including a cohort of 3,000
people over 74 years of age, supports the efficacy
of DHP CCBs in reducing or delaying the develop-
ment of AD [44]. The recent Systolic Hypertension
in Europe randomized control trial reported a 55%
reduction in the incidence of dementia in people
taking nitrendipine over a 5-year follow-up period
[46].
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The neuroprotective mechanism of CCBs is poorly
understood. In the presence of CCBs, amyloid-
(A) production, aggregation, and neurotoxicity is
decreased, improving neuronal function both in vitro
and in vivo [38, 40]. BAY w 9798 is a DHP struc-
turally related to the Ca-antagonist nifedipine with
anti-inflammatory and anti-oxidative properties but
with no calcium antagonistic effects [47]. Because
lipophilic compounds DHPs bind to the membrane
lipid bilayer, they potentially act indirectly as allo-
network drugs via the propagation of changes in
cellular networks. In fact, lipid bilayer partitioning
of DHPs occurs prior to the drug binding to receptors
[48, 49]. Changes in the lipid phase of membranes
alter cell signaling [50, 51], which is also asso-
ciated with a variety of diseases including NDDs.
Modulation of the cell membrane composition and
structure as a molecular base for drug discovery and
new disease treatment was recently reviewed and
the term “membrane lipid therapy” was introduced
[52].
Hsp co-inducer hydroxamic acid derivatives can
normalize the dysregulated expression of Hsps in
pathological conditions and interact with membranes,
resulting in specific alterations in the membrane
nanostructure [53–55]. We searched for novel sub-
stances that do not directly exert stress on cells, but
have long-term effects on cellular stress responses
and viability (co-inducing activity). Such Hsp co-
inducer compounds potentiate the response to a
pre-existing stress without exhibiting effects in non-
stressed environments. These compounds provide a
higher degree of selectivity affecting only the dis-
eased/damaged tissue compared with non-specific
stressors. They also augment normal physiologic
stress response systems rather than just blocking or
activating a single enzyme that likely leads to a com-
pensatory feedback loop, counteracting its long-term
benefits.
The aim of this study was to investigate the ben-
eficial effect of Hsp co-inducers in a mouse model
of AD. A family of novel co-inducer compounds
was synthesized [56] from which three were selected
for further investigations (LA1011, LA1030, and
LA1044). The co-inducing effect of Hsp27, Hsp40,
and Hsp70 was verified. The neuroprotective effect
of the optimized compound LA1011 was demon-
strated in the APPxPS1 AD transgenic mouse model
using a spatial navigation test. Histology studies of
mouse brain slices were performed to investigate neu-
ronal viability, changes in dendritic spine density and
the presence of A and tau-pathology-characteristic
abnormalities in AD [57].
MATERIALS AND METHODS
Preparation and optimization of
1,4-dihydropyridines
BAY w 9798 [58] was selected as a starting
compound in our study [56]. During optimization
using standard dihydropyridine synthetic protocols,
the substituents at positions 1, 2, 4, and 6 were mod-
ified systematically, resulting in LA1030, a more
lipophilic compound with improved activity. To aug-
ment the oral bioavailability of the compounds, one or
two cationic centers were introduced to substituents at
positions 2 and 6. LA1011 and LA1044 were the most
active compounds. The compounds were synthesized
using conventional techniques from commercially
available starting materials [59–63] (Fig. 1). Com-
pounds were characterized by melting point and
1H-NMR data (recorded on a DRX 400 MHz Bruker
spectrometer).
Synthesis of LA1011
Dihydropyridine (1 mmol), 5 mmol dimethylam-
ine-hydrochloride, 5 mmol paraformaldehyde, and
1 ml acetic acid were mixed and heated at 95◦C
for 5 h. The mixture was evaporated, dissolved in
water and extracted with ether. After separation, the
aqueous phase was neutralized with NaHCO3 and
extracted with ethyl acetate. The organic phase was
dried and evaporated, and the residue was purified
by column chromatography on silica with a mixture
of hexane/ethyl acetate. The pure fractions were col-
lected, transferred to hydrochloride or to other salts,
and recrystallized from methanol diethyl ether. The
melting point (Mp) was 273–276◦C. 1HNMR data:
D2O, 400 MHz, δ: 7.51 (d, J= 8.3 Hz, 2 H, ArH), 7.28
(d, J= 8.6 Hz, 2 H, ArH), 5.07 (s, 1 H, CH), 3.67 (s,
6 H, COOCH3), 3.14–3.59 (m, 11 H, -CH2-, -CH3),
2.87 (s, 12 H, -CH3).
Synthesis of LA1030
A mixture of 0.05 mol p-trifluoromethyl benzalde-
hyde, 0.1 mol methyl 3-oxovaleroate, and 0.05 mol
methylamine hydrochloride was refluxed in 25 ml
pyridine for 5 h. The residue was dissolved in
dichloromethane and washed with water after evap-
oration of the solvent. The organic phase was dried
and evaporated. The residue was crystallized from
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Fig. 1. Chemical structure of the synthesized 1,4-dihydropyridine derivatives.
methanol. The Mp was 133–138◦C; 1HNMR data:
CDCl3, 400 MHz, δ: 7.39 (d, J= 8.6 Hz, 2 H, ArH),
7.21 (d, J= 8.6 Hz, 2 H, ArH), 5.08 (s, 1 H, CH), 3.67
(s, 6 H, COOCH3), 3.14 (s, 3 H, N-CH3), 2.99–3.11
(m, 2 H, -CH2-), 2.71–2.84 (m, 2 H, -CH2-),
1.06–1.12 (m, 6 H, CH3).
Synthesis of LA1044
Compound LA1044 was transformed to the
2-bromomethyl derivative in pyridine with pyridini-
umbromoperbromide [62]. One mmol of this product
was dissolved in 10 ml acetonitrile and 2 eq. of
K2CO3 and 1.1 eq. of 1,2,3,4-tetrahydroisoquinoline
was then added. The mixture was stirred until the
reaction was complete, then filtered and evaporated,
and the residue was purified by chromatography.
The Mp was 175–177◦C; 1HNMR data: CDCl3,
400 MHz, δ: 7.47 (d, J= 8.2 Hz, 2 H, ArH), 7.29
(d, J= 8.2 Hz, 2 H, ArH), 7.06–7.16 (m, 3 H, ArH),
6.91–6.97 (m, 1 H, ArH), 5.22 (s, 1 H, CH), 4.20
(d, J= 14.2 Hz, 1 H, C-CH2-N), 3.80 (d, J= 14.2 Hz,
1 H, C-CH2-N), 3.73 (s, 3 H, COOCH3), 3.72 (s, 3 H,
COOCH3), 3.58–3.69 (m, 2 H, CH2), 3.35 (s, 3 H,
N-CH3), 2.67–2.85 (m, 4 H, CH2), 2.48 (s, 3 H, CH3).
Measurement of Hsp co-inducing activity
The effect of drug candidates on the stress
response was tested with the SH-SY5Y (ATCC®
CRL-2266™) human neuroblastoma cell line sta-
bly transfected with a plasmid containing the Hsp70
promoter fused to yellow fluorescent protein (YFP)
(pEYFP-N1, Clontech), a kind gift of Lea Sis-
tonen (A˚bo Akademi University, Turku, Finland)
(SH-SY5Y-pHsp70-YFP). Cells were maintained in
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a logarithmic-phase of growth on 100 mm dishes
(Orange Scientific, Braine-l’Alleud, Belgium) in
DMEM-F12 (1:1) medium (Life Technologies, NY,
USA) supplemented with 10% heat-inactivated fetal
bovine serum (Life Technologies). Cultures were
maintained at 37◦C in a humidified atmosphere
incubator with 5% CO2. When cells reached 80%
confluence, they were harvested in Trypsin/EDTA
Solution (Lonza, Basel, Switzerland) and were plated
at a density of 5× 105 cells/6-cm culture dishes
(Orange Scientific). After 24 h, cells were pre-
incubated either with or without LA1011 (5 M)
or LA1044 (40 M) for 30 min. Following pre-
incubation, plates were divided into two groups: The
control group was maintained at 37◦C for 17 h and
the other was heat-shocked at 42◦C for 1 h and then
placed back at 37◦C for a 16 h recovery period (HS
group). After recovery the expression of YFP, which
is directly correlated to the activity of its Hsp70
promoter, was followed by measuring the fluores-
cence intensity of the cells with a BD Accuri C6
flow cytometer (Becton, Dickinson and Company,
NJ, USA) [64].
Western blot analysis
SH-SY5Y cells were grown and treated with
the drug candidates and heat exactly as described
above. Following the recovery, cells were extracted
in RIPA (radioimmunoprecipitation assay) buffer.
Cell lysates were constantly agitated at 4◦C for
2 h then centrifuged at 12,000× g for 1 min and
supernatants were saved. After determining the
protein concentration (BCA assay kit, Thermo Sci-
entific, Rockford, IL, USA), 20 g of total protein
was separated by sodium dodecyl sulfate polyacry-
lamide gel electrophoresis under reducing conditions
according to the method of Laemmli [65]. Pro-
teins were blotted onto polyvinylidene difluoride
membranes (Immobilon-P; Millipore, MA, USA).
The blot was incubated overnight at 4◦C in the
presence of -Hsp27 (ADI-SPA-803), -Hsp70
(ADI-SPA-810), -Hsp60 (ADI-SPA-806), -Hsp90
(ADI-SPA-830) (Enzo Life Sciences, NY, USA), and
-Hsp40 (C-20:sc-1800, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), antibodies diluted 1:1000
in phosphate-buffered saline solution (PBS). After
overnight incubation, the membrane was washed
three times in PBS–0.05% Tween and incubated
for 1 h in peroxidase-conjugated anti-mouse, anti-
rabbit or anti-goat IgG antibody (Sigma-Aldrich, St.
Louis, MO, USA) diluted 1:50,000 in PBS con-
taining 3% non-fat dry milk powder. The immune
complexes were detected using enhanced chemi-
luminescence (ECL) (Amersham, Little Chalfont,
Buckinghamshire, UK) according to the supplier’s
instructions and analyzed using AlphaEase FC
software (Alpha Innotech, San Leandro, Canada).
Immunoreactive bands were normalized to the den-
sity -GAPDH (1:20,000) (G9545; Sigma-Aldrich)
from the same sample.
Cytotoxicity assays
In vitro test: SH-SY5Y cells were homogenously
distributed on 96-well plates in 5× 103 cells/well
density and incubated at 37◦C. Then, 24 h later,
cells were treated with LA1011, LA1030 or LA1044
at a 100 nM-200 M concentration range for 24 h.
The viability of the cells was measured using
alamarBlue® assay kit (Life Technologies) according
to the supplier’s instructions. The in vivo acute toxi-
city of drugs selected for animal experiments were
assayed in 2-month-old BALB/c mice (n= 10) by
injecting the compound in PBS solution intraperi-
toneally (ip) at a 300 mg/kg dose.
Measurement of neuroprotection
Animals and treatments
B6C3-Tg (APPswe/PS1dE9)85Dbo/Mmjax mice
(APPxPS1) were purchased from The Jackson Lab-
oratory (Bar Harbor, ME, USA) and maintained on
the C57BL/6 genetic background (tg). The mice were
kept in individual ventilated cages (Ace´llabor Ltd.,
Hungary) on a 12/12 h dark/light cycle (lights on from
7 a.m. to 7 p.m.) with food and water available ad libi-
tum and were treated ip with 3 mg/kg LA1011 once
a day for 6 months. Four groups (8 animals/group)
of 3 months old male mice were used: 1) wild type
(C57BL/6) mice (wt) treated with saline; 2) wt treated
with LA1011; 3) tg treated with saline; and 4) tg
treated with LA1011.
Animal care followed the Communities Council
Directive of 22 September 2010 (2010/63/EU on
the protection of animals used for scientific pur-
poses). Formal approval to conduct the experiments
described was obtained from the Animal Experimen-
tation Committee of the University of Szeged.
Behavioral test
The Morris water maze (MWM) is one of the
most commonly used experimental rodent models
to measure spatial learning and memory [66–73].
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Animals were trained in an open-field water maze
(diameter: 130 cm) filled with water (23± 1◦C) made
opaque with milk. The pool was divided into four
virtual quadrants and the invisible platform (diam-
eter: 10 cm) was submerged in the middle of one
of the four quadrants. Around the pool there was
a black curtain. The animals swam twice a day for
5 consecutive days, and were launched from four
different starting points. They were placed into the
water facing the wall of the pool and were given 90 s
to find the platform and 15 s to stay on it. Animals
that did not find the platform were gently guided
and placed on it. The escape latency data were cal-
culated automatically by a video tracking system
(EthoVision 2002, Noldus Information Technology,
Netherlands).
Histology studies
After the MWM test, the mice were deeply anes-
thetized and transcardially perfused with 10 ml of 4◦C
PBS, followed by 30 ml of 4◦C paraformaldehyde
solution (4% in phosphate buffer, pH 7.4). Mouse
brains were removed and post-fixed for 24 h in the
same fixative (4◦C), and subsequently placed in a
30% sucrose solution for 72 h at 4◦C. Hippocampal
coronal sections were cut to 30 m on a cryostat, and
the slices were collected and stored at 4◦C in PBS for
free floating histochemistry.
Cresyl violet (Nissl) staining
Cresyl violet readily binds to the acidic compo-
nents of RNA-rich ribosomes, as well as the nuclei
and nucleoli of nerve cells and is used to determine
neuron density. Slices (n= 4, 2 slice/animal) were
mounted on slides and stained in filtered 1% cresyl
violet solution for 5 min and dehydrated subsequently
in 50% 70%, 95%, and twice in 100% ethanol for
1 min each. Slides were finally placed in xylene for
another 10 min and coverslipped. Digital images were
captured by a digital slide scanner (Mirax Midi, Carl
Zeiss, Hungary), and analysis was performed using
the Histoquant program (3DHistech, Hungary).
Tau immunohistochemistry
After quenching of endogenous peroxidase activ-
ity and non-specific blocking, the sections (n= 4,
4 slices/animals) were incubated overnight at 4◦C
with paired helical filament (PHF)-tau monoclonal
antibody (clone AT100, Pierce Biotechnology, USA)
at a 1:800 dilution in PBS (pH 7.4) in the pres-
ence of 20% goat serum and 0.2% Triton X-100.
On the following day, the sections were washed
in PBS and incubated for 1 h at room temperature
with biotinylated goat anti-mouse antibody (1:400)
followed by 1 h incubation with avidin-biotin com-
plex (Vectastain Elite ABC Kit, Vector Laboratories,
Burlingame, CA, USA; 1:400). After washing, sec-
tions were incubated in peroxidase substrate solution
(nickel-enhanced 3,3′-diaminobenzidine) until the
desired stain intensity developed. Following rinsing
in tap water, sections were mounted on gelatin-coated
slides, air-dried, dehydrated, and coverslipped with
DPX mountant for histology (Fluka BioChemika,
Buchs, Switzerland). Digital images were captured
by a digital slide scanner (Mirax Midi), and anal-
ysis was performed using the Histoquant program
(3DHistech).
Quantification of dendritic spine density using
Golgi impregnation
The FD Rapid GolgiStain™ Kit (FD NeuroTech-
nologies, Consulting & Services, Inc., Columbia,
MD, USA) was used (n= 3, 1 slice per animal and 2
neurons per slice) to measure dendritic spine density
in the hippocampal CA1 area. Experimental animals
were deeply anesthetized before brains were removed
as quickly as possible and then carefully handled to
avoid damage or pressing of the tissue. The tissue was
immersed in an impregnation solution (A + B solu-
tion) and stored at room temperature for 2 weeks in
the dark. The brains were transferred into another
solution (C) and stored at 4◦C in the dark for at least
48 h. Then, 100-m thick coronal sections were cut
with a microtome (Zeiss Microm HM 650 V). Sec-
tions were mounted on gelatin coated glass slides.
After the staining and dehydration procedure, the
slides were covered with DPX (VWR International,
Radnor, PA, USA).
Golgi sections were studied by inverse light
microscopy using oil-immersion objectives. The
spine density of the proximal apical dendrite area
was analyzed (100–200 m from soma). One seg-
ment (100 m in length) from a second-third-order
dendrite protruding from its parent apical dendrite
was chosen in each examined neuron for spine density
quantification, as described by Nagy et al. [74]. The
dendrites were selected under a 100× oil immersion
lens and the images (600×) of these apical dendrites
were captured through a CCD camera (1,600× 1,200
pixel) connected to a light microscope (Olympus
Vanox-T AH-2) and a computer. Serial images were
captured from each dendrite in the analyzed segment.
The captured multiple photomicrographs from one
dendrite were then stacked into one file. To stack
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Fig. 2. The Hsp70 co-inducer effect of various LA drug candidates
was screened by using a promoter-probing assay. Bars represent-
ing co-induction were calculated by the following formula: Fold
change = [(Fx(42)-F0(37)]/[F0(42)-F0(37)], where “F” represents
the fluorescent intensity of cells incubated in the absence “0” or
presence of drug candidates of concentration “x” at 37◦C or 42◦C
for 1 h. The missing bars for LA1011 (20 and 40 M) indicate that
the drug was toxic at these concentrations. Data are means±SD.
the images Image- Pro-Plus image analysis software
(IPP; Media Cybernetics, Silver Spring, MD, USA)
was used. Measurement of the spine density was per-
formed by two independent experimenters to blind
the analysis.
Statistical analysis
For statistical evaluation of western blots (Fig. 3),
one-way ANOVA with post hoc Games-Howell test
was used, which was performed by R 3.1.1 for Win-
dows software. Data represent the mean± standard
deviation (SD) (n= 6) (Figs. 2 and 3). A p< 0.05
value was considered statistically significant. Statis-
tical analysis of the Morris water maze experiment
(Fig. 4) was performed using SPSS software and
Python’s Lifelines library (Davidson-Pilon, C., Life-
lines, 2016), Github repository. The latency time to
attain the platform (with a 90-s limit) was measured
to determine which of the four groups had the highest
learning rate. The longer the latency time to the plat-
form is, the lower the learning capacity of the mice.
“Survival curves” using the Cox Proportional Hazard
model [75] were fitted, and the days and the treat-
ments were selected as covariates. The comparison
of treatment groups was performed using log-rank
tests.
One-way ANOVA followed by Fisher’s LSD post
hoc test was used for histological analysis and for
dendritic spine density measurements (Fig. 5) using
SPSS statistical software. Differences with a p-value
of less than 0.05 were considered significant unless
indicated otherwise.
RESULTS
Hsp co-inducing activity of LA1011, LA1030,
and LA1044
We used SH-SY5Y human neuroblastoma cells
stably expressing YFP under the control of an Hsp70
promoter to select the non-toxic concentrations of
active Hsp co-inducing compounds (data not shown).
In addition to the original lead compound (BAY
w 9798), we investigated the effects of three novel
drug candidates (LA1011, LA1030, and LA1044) on
Hsp70 promoter activity (Fig. 2).
The drug candidates were added to SH-SY5Y-
pHsp70-YFP cells at the four indicated concentra-
tions 30 min prior to heat treatment (42◦C, 1 h), which
was followed by a 16 h recovery period at 37◦C. After
recovery, the expression of YFP was determined by
flow cytometry. At 37◦C none of the compounds
had a significant effect on Hsp70 promoter activity
(data not shown); however, at an elevated temperature
(42◦C) pronounced expression of YFP was observed
(2-3 fold increase in intensity), which was further
increased by administering the LA compounds, thus
indicating the co-induction property of these drug
candidates (Fig. 2). From these highly active “hit”
molecules we chose water soluble LA1011 and water
insoluble LA1044 for further in vitro and in vivo
investigations.
The Hsp co-inducing effect of LA1011 and
LA1044 on different Hsp-classes in SH-SY5Y
cells was studied by western blot. Representative
immunoblots (Fig. 3) demonstrate that heat shock
induced Hsp27, Hsp40, and Hsp70 proteins; how-
ever, the level of Hsp60 and Hsp90 remained
unchanged (Supplementary Figure 1). The admin-
istration of LA1011 (5 M) and LA1044 (40 M)
further increased the level of Hsp27, Hsp40, and
Hsp70. Importantly, in the absence of heat shock (cel-
lular stress), these compounds did not alter the level
of any Hsps measured. Results summarized in Fig. 3
demonstrate the unique Hsp co-inducer properties of
LA1011 and LA1044, as they act only during stress.
Inhibition of the ATPase activity of Hsp90 by nat-
urally identified antibiotics and synthetic molecules
is well-documented [76, 77] and is a known mecha-
nism for the upregulation of the heat shock response.
We therefore tested the ability of LA1011 to modu-
late the ATPase activity of yeast Hsp90. We found
that LA1011 did not modify the ATPase activity
of yeast Hsp90 at concentrations of 5 and 10 M
(Supplementary Figure 2).
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Fig. 3. Effect of heat and LA1011 or LA1044 treatment on Hsp70, Hsp27 and Hsp40 levels in SH-SY5Y human neuroblastoma cell line
measured by western blotting (A, B) and quantitative densitometric analysis (C, D). Cells were untreated or treated with LA1011 (5 M) or
LA1044 (40 M) at 37◦C or 42◦C. Box plots represent quantitative data normalized to GAPDH. All data represent the mean±SD (n= 6)
and p< 0.05 was considered statistically significant. HS = heat shock at 42◦C, 1 h. ∗p< 0.05, when data are compared to LA compound (–),
HS (–) sample. #p< 0.05, when data are compared to LA compound (–), HS (+) sample. One way ANOVA followed by a Tukey post hoc
test was used for statistical comparisons.
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Fig. 4. Effect of LA1011 treatment on Morris water maze per-
formance. The fitted survival curves using the Cox Proportional
Hazard model represents the probability that animals find the
platform during a trial, capped at 90 s. The effect of day has
been modeled in. We compared wt+saline versus wt+LA1011
(p= 0.047), wt+saline versus tg+saline (p= 0.036), and tg+saline
versus tg+LA1011 (p= 0.001) treatment groups using log-rank
tests (n= 8/group).
In vivo neuroprotective effect of LA1011
After the acute toxicity test (at 300 mg/kg) was
negative, the neuroprotective effect of the Hsp co-
inducer LA1011 was studied in tg mice using
behavioral and histological methods. The applied
chronic dosage of 3 mg/kg for the in vivo experiments
was selected based on the in vitro results.
Spatial navigation in MWM
After 6 months daily ip treatment of mice with
either LA1011 (3 mg/kg) or saline, the MWM test
was applied. The animals were placed into the
water facing the sidewalls of the pool at differ-
ent starting positions across trials, and the swim
time to find the platform (escape latency) was fol-
lowed with a tracking system. The animals learned
to swim to the correct location with decreasing
escape latencies across days (Supplementary Fig-
ure 3). Pairwise comparison of daily performances
was made using the log-rank test and included all
mice. Compared to day one of testing, mice were
more likely to find the platform on day two (p= 1.65e-
5), day three (p= 5.24e-6), day four (p= 1.88e-11),
and day five (p= 4.55e-12). The probability to reach
the platform was determined using the Cox Propor-
tional Hazard model (Fig. 4). Significant differences
were found between wt+saline versus wt+LA1011
(p= 0.047), wt+saline versus tg+saline (p= 0.036),
and tg+saline versus tg+LA1011 (p= 0.001) treat-
ment groups. Importantly, mice in the tg+saline group
required significantly more time to find the platform
compared to the wt+saline group; however, the 6
months daily ip LA1011 treatment tg mice showed
a significantly improved learning ability (tg+saline
versus tg+LA1011p= 0.001). Interestingly, we found
LA1011 improved the memory potency (procogni-
tive) of mice as wt+LA1011 treated mice required
less time to complete the task compared with controls
(wt+saline) (p= 0.047).
Histology
The animals were treated as described in “Ani-
mals and treatments”. Brain sections (prepared as
described in “Materials and Methods”) were stained
with cresyl violet, which stain Nissl substance in
the cytoplasm of neurons in paraformaldehyde or
Fig. 5. Cresyl-violet staining, tau-immunostaining, and Golgi-Cox staining of hippocampal slices of wt and tg animals after 6 months treat-
ment. (A) Number of counted neurons/mm2; n= 4, 2 slices/animal, (B) number of counted neurofibrillary tangles/mm2; n= 4, 4 slices/animal
and (C) measured spine density/100 m; n= 3, 2 slices/animal. Each dot represents the counted raw data, while horizontal bars indicate
mean values. Statistical significance was determined by one-way ANOVA, followed by Fisher’s LSD post hoc test. Differences with a
p-value <0.05 were considered significant; n refers to the number of animals.
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formalin-fixed tissue. Digital images were analyzed
by HistoQuant program. The difference in the num-
ber of neurons was significant between the groups
(Fig. 5A–D). Significantly fewer neurons were
observed in the tg+saline group compared with the wt
group (tg+saline versus wt+saline group, p= 0.002).
Cresyl-violet staining confirmed that LA1011 was
neuroprotective in the transgenic AD mouse model.
Treating mice with LA1011 for 6 months signifi-
cantly prevented the loss of neurons in this group
(tg+saline versus tg+LA1011, p= 0.041).
Tau-pathology studies used immunohistochem-
istry to detect tau in PHF, a major component of the
neurofibrillary tangles (NFTs) involved in the pathol-
ogy of AD that are not present in normal biopsies
[78]. Digital images were analyzed by HistoQuant
program. There were significant differences in the
number of abnormally accumulated NFTs in the
hippocampus (HC) between the groups (p= 0.001)
(Fig. 5B; Supplementary Figure 4E–H). There were
more NFTs in the HC slices of the tg+saline group
compared with the wt+saline group (p= 0.001). Most
importantly, the administration of Hsp co-inducer
LA1011 decreased the number of NFTs in tg mice
HC to the level found in the HC of wt mice (p= 0.001)
(Fig. 5B).
Long-term memory is mediated in part by the
growth of new dendritic spines (or the enlargement
of pre-existing spines) to reinforce a particular neural
pathway. According to the literature, APPxPS1 mice
undergo spine loss already by the age of 4 months
[79]. One of the best neurohistological methods to
observe detailed morphology of neurons is Golgi
staining. The Golgi-Cox protocol can be used to study
the experimental effects of different pharmacological
manipulations on the spatial distribution of neurons,
dendrite density, spine number, and morphology.
After the Golgi-Cox staining of the HC CA1 area, dig-
ital images were used to count dendritic spines. The
tg+saline group had fewer dendritic spines compared
with the wt+saline group (p= 0.045). The 6-month
LA1011 treatment of transgenic animals resulted in
a considerably greater number of spines in the HC
slices (tg+saline versus tg+LA1011; p= 0.001). The
treatment did not affect the spine number of wt ani-
mals. This could be explained by the molecule’s
“HSP co-modulating activity” namely it acts like
“smart molecules” by selective interactions with
only those cells, which are under acute or chronic
stress.
A peptide initiates inflammation in the HC of
the human brain in AD. A is chemically “sticky”
and gradually builds up into plaques [57], which
can be identified by immunohistochemistry using
anti-A antibody. We observed amyloid plaque-like
structures in tg mice (Supplementary Figure 4I–L).
The representative examples of sections show a nos
amount of plaque formation in the HC of transgenic
saline treated animals compared to that of wt samples.
Administering LA1011 to tg mice decreased plaque
formation (Supplementary Figure 4K, L). There were
no signs of amyloid plaques in sections from wt ani-
mals (Supplementary Figure 4I, J).
DISCUSSION
At present, there are few drugs that improve the
memory deficits associated with normal aging and
none that prevent cognitive decline in chronic neu-
rodegenerative conditions such as AD. Except for rare
cases of familial AD, the cause of AD is not known,
but disease is highly correlated with aging, a process
involving a wide variety of physiological changes.
Therefore, it is likely that cells in the aging brain
are compromised not from a single cause but from
the convergence of multiple insults. Unfortunately,
drug candidates for AD have all failed in clinical tri-
als, perhaps because one target is not sufficient or
because the targets are also critical for normal brain
function. Molecular chaperones have central roles in
each of the arms of cellular proteostasis (synthesis,
folding, disaggregation, and degradation of pro-
teins); therefore, the approach described in this study,
the administration of Hsp co-inducer 1,4 DHPs,
might have therapeutic benefits for NDDs including
AD.
The most important finding of this study is that
the novel Hsp co-inducer is broadly neuroprotective
and has the ability to enhance memory in normal
animals as well as to prevent memory deficits in
AD transgenic mice. The neurotrophic and memory-
enhancing activities of LA1011 might be associated
with an increase in the levels of Hsp70, Hsp40, and
Hsp25.
The Hsp co-inducer effect of the novel 1,4-DHP
compounds LA1011 and LA1044 was demonstrated
in vitro by a promoter probing assay (Fig. 2), and by
western blot in a SH-SY5Y human neuroblastoma
cell line (Fig. 3). The inhibition of the ATPase activity
of Hsp90 is a known mechanism for the upregulation
of the heat shock response. We therefore tested the
ability of LA1011 to modulate the ATPase activity of
yeast Hsp90 and found that LA1011 did not modify
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the ATPase activity of yeast Hsp90 at concentrations
of 5 and 10 M (Supplementary Figure 2).
The observed Hsp modulating activity of the
compounds was separable from the Ca2+ channel
antagonist effect responsible for the antihypertensive
activity of many known 1,4-DHPs. For the known
Ca2+ channel antagonist nilvadipine, the EC50 for
Hsp-modulation and for Ca2+ channel inhibition is
equal [56, 80]. The EC50 for the novel compounds
described in this study was above 10; thus, the sep-
aration of a potential antihypertensive effect allows
the selected compounds to be used to treat pathophys-
iological conditions mediated by Hsps, including
NDDs, without the risk of hypotension. The best
co-inducer, LA1011 was selected for in vivo exper-
iments in the tg mouse model of AD and proved to
be neuroprotective. LA1011 prevented neuron loss
in the HC of tg mice (Fig. 5A), decreased NFT
accumulation (Fig. 5B), and saved dendritic spine
numbers (Fig. 5C). In the MWM task, both wt groups
showed a progressive decrease in latency to reach
the platform, a measure of spatial learning. Tg ani-
mals, however, showed significantly higher latencies
compared to all other experimental groups sugges-
tive of delayed learning. In line with the histological
results, 6 months treatment with LA1011 signifi-
cantly restored the spatial learning capability of tg
mice (p= 0.001) and further improved the memory
of wt animals (Fig. 4). These results can be explained
in the context of our knowledge of the pathogenetic
mechanisms of AD. Furthermore, maintenance of
protein homeostasis by chaperone induction predicts
the induction of a beneficial effect of LA1011 on brain
function and morphology.
AD is a complex, multifactorial syndrome
with a number of leading mechanisms, including
astrocyte hyperactivity (reactive astrogliosis), neu-
roinflammation, mitochondrial dysfunction, and the
accumulation of misfolded proteins (A, NFT, -
synuclein) in the brain [57]. A net loss of dendritic
spines is observed in AD and cases of intellectual
disability. Because dendritic spines are plastic struc-
tures whose lifespan is influenced by input activity
[81], spine dynamics may play an important role in
the maintenance of memory over a lifetime.
The original A hypothesis of Hardy states that an
imbalance exists between A production and clear-
ance resulting in A accumulation [82, 83]. During
the last 20 years, intensive research has targeted the
biosynthesis of A (-and -secretases), as well as
the clearance of A and amyloid plaques from the
brain [84]. However, these trials were unsuccessful
and no efficient drug treatment of AD exists currently,
although a number of novel AD drug trials are in
progress.
Recent data on the molecular basis of AD patho-
physiology suggest a number of leading mechanisms
[85]. Mitochondrial DNA mutations leading to oxida-
tive stress-induced mitochondria dysfunction triggers
a chain of cellular events leading to neurodegener-
ation and a “vicious circle” that ends in dementia
[86, 87]. Molecular chaperones and the ubiquitin-
proteasome system represent the most important
defensive mechanisms against misfolded proteins
in AD [88]. Each protein aggregation disease can
be characterized by a different set of Hsps that
can rescue specific types of aggregation [89]. Some
of these Hsps have demonstrated effectiveness in
vivo, in mouse models of protein-aggregation dis-
eases. Hsp70 and Hsp90 promote tau solubility and
tau binding to microtubules, reduce insoluble tau,
and reduce tau hyperphosphorylation in a transgenic
mouse model of AD [90]. In addition, therapeu-
tic inducers of the Hsp70/Hsp110 system protected
Hsp-deficient mice against traumatic brain injury
[30] and the upregulation of Hsp by geldanamycin
reduced brain injury in a mouse model of intracere-
bral hemorrhage [33]. A molecular chaperone, the
human BRICHOS domain, can specifically inhibit
the A-catalytic cycle (A1-42 fibrils effectively cat-
alyze the formation of neurotoxic A-oligomers)
and limit human A1-42 toxicity [91]. In addition,
some molecular chaperones forcibly untangle protein
aggregates (disaggregases) [92]. Omi/HtrA2, a mam-
malian chaperone, selectively binds and detoxifies
oligomeric A by disaggregation [93]. Exogenous
human Hsp70 had dramatic neuroprotective effects
in olfactory bulbectomy mice and 5xFAD mouse
models of neurodegeneration [29] based on its
anti-apoptotic and anti-inflammatory effects. Conse-
quently, small molecule activators of the heat shock
response provide great therapeutic promise [94].
Ca2+-dependent activation of heat shock factor 1
suppressed protein misfolding and reprograming of
protein homeostasis [95]. Arimoclomol, an Hsp co-
inducer, may protect motor neurons by enhancing
Hsp expression, thus directly affecting protein aggre-
gation and clearance of misfolded assemblies via
the proteasome-ubiquitin system [32]. Recent exper-
iments have demonstrated the dual role of Hsp70
[96], which functions as a molecular chaperone for
damaged proteins, as well as simultaneously stabi-
lizing lysosomes, which can revert NDD-associated
lysosomal pathology [96–98].
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In summary, unregulated Hsp induction could
cause the excessive overexpression of Hsps leading
to instability of the stress response and unwanted side
effects [99]. Because LA1011 and LA1044 increase
Hsp expression only under stressed conditions, the
therapeutic use of DHPs in this study is novel and
perhaps an optimal strategy for the treatment of AD
and other NDDs.
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